新咪唑吡啶-希夫碱衍生物的合成、晶体结构和抗病毒评价:体外和硅学抗艾滋病毒研究†。

IF 3.9 3区 化学 Q2 CHEMISTRY, MULTIDISCIPLINARY
RSC Advances Pub Date : 2024-11-19 DOI:10.1039/D4RA07561G
Mohamed Azzouzi, Abderrahim Ait Ouchaoui, Omar Azougagh, Salah Eddine El Hadad, Mohamed Abou-salama, Adyl Oussaid, Christophe Pannecouque and Taoufik Rohand
{"title":"新咪唑吡啶-希夫碱衍生物的合成、晶体结构和抗病毒评价:体外和硅学抗艾滋病毒研究†。","authors":"Mohamed Azzouzi, Abderrahim Ait Ouchaoui, Omar Azougagh, Salah Eddine El Hadad, Mohamed Abou-salama, Adyl Oussaid, Christophe Pannecouque and Taoufik Rohand","doi":"10.1039/D4RA07561G","DOIUrl":null,"url":null,"abstract":"<p >A series of Imidazo[1,2-<em>a</em>]pyridine-Schiff base derivatives were synthesized and characterized using <small><sup>1</sup></small>H NMR, <small><sup>13</sup></small>C NMR, Mass Spectrometry and FTIR techniques, and the structure of <strong>4a</strong> was further confirmed through single-crystal X-ray diffraction analysis. Density Functional Theory (DFT) has been used to investigate the structural and electronic properties. The synthesized compounds were evaluated <em>in vitro</em> for their antiviral activity against human immunodeficiency virus type-1 (HIV-1) and human immunodeficiency virus type-2 (HIV-2) in MT-4 cells. Compound <strong>4a</strong> displayed EC<small><sub>50</sub></small> values of 82,02 and 47,72 μg ml<small><sup>−1</sup></small> against HIV-1 and HIV-2, respectively. Molecular docking studies were conducted to gain insights into the interaction mechanism of the synthesized compounds with HIV-1 reverse transcriptase. ADME analysis suggested acceptable pharmacokinetic profiles, though solubility remains a limitation for these compounds, highlighting the need for further structural modifications to enhance bioavailability and therapeutic potential.</p>","PeriodicalId":102,"journal":{"name":"RSC Advances","volume":" 50","pages":" 36902-36918"},"PeriodicalIF":3.9000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2024/ra/d4ra07561g?page=search","citationCount":"0","resultStr":"{\"title\":\"Synthesis, crystal structure, and antiviral evaluation of new imidazopyridine-schiff base derivatives: in vitro and in silico anti-HIV studies†\",\"authors\":\"Mohamed Azzouzi, Abderrahim Ait Ouchaoui, Omar Azougagh, Salah Eddine El Hadad, Mohamed Abou-salama, Adyl Oussaid, Christophe Pannecouque and Taoufik Rohand\",\"doi\":\"10.1039/D4RA07561G\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >A series of Imidazo[1,2-<em>a</em>]pyridine-Schiff base derivatives were synthesized and characterized using <small><sup>1</sup></small>H NMR, <small><sup>13</sup></small>C NMR, Mass Spectrometry and FTIR techniques, and the structure of <strong>4a</strong> was further confirmed through single-crystal X-ray diffraction analysis. Density Functional Theory (DFT) has been used to investigate the structural and electronic properties. The synthesized compounds were evaluated <em>in vitro</em> for their antiviral activity against human immunodeficiency virus type-1 (HIV-1) and human immunodeficiency virus type-2 (HIV-2) in MT-4 cells. Compound <strong>4a</strong> displayed EC<small><sub>50</sub></small> values of 82,02 and 47,72 μg ml<small><sup>−1</sup></small> against HIV-1 and HIV-2, respectively. Molecular docking studies were conducted to gain insights into the interaction mechanism of the synthesized compounds with HIV-1 reverse transcriptase. ADME analysis suggested acceptable pharmacokinetic profiles, though solubility remains a limitation for these compounds, highlighting the need for further structural modifications to enhance bioavailability and therapeutic potential.</p>\",\"PeriodicalId\":102,\"journal\":{\"name\":\"RSC Advances\",\"volume\":\" 50\",\"pages\":\" 36902-36918\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-11-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pubs.rsc.org/en/content/articlepdf/2024/ra/d4ra07561g?page=search\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"RSC Advances\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2024/ra/d4ra07561g\",\"RegionNum\":3,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"RSC Advances","FirstCategoryId":"92","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/ra/d4ra07561g","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

摘要

利用 1H NMR、13C NMR、质谱和傅立叶变换红外光谱技术合成并表征了一系列咪唑并[1,2-a]吡啶-席夫碱衍生物,并通过单晶 X 射线衍射分析进一步证实了 4a 的结构。密度泛函理论(DFT)被用来研究化合物的结构和电子特性。对合成的化合物在 MT-4 细胞中对人类免疫缺陷病毒 1 型(HIV-1)和人类免疫缺陷病毒 2 型(HIV-2)的抗病毒活性进行了体外评估。化合物 4a 对 HIV-1 和 HIV-2 的 EC50 值分别为 82.02 和 47.72 μg ml-1。为了深入了解合成化合物与 HIV-1 逆转录酶的相互作用机制,我们进行了分子对接研究。ADME 分析表明这些化合物具有可接受的药代动力学特征,但溶解性仍然是其局限性,这突出表明有必要进一步进行结构改造,以提高生物利用度和治疗潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Synthesis, crystal structure, and antiviral evaluation of new imidazopyridine-schiff base derivatives: in vitro and in silico anti-HIV studies†

Synthesis, crystal structure, and antiviral evaluation of new imidazopyridine-schiff base derivatives: in vitro and in silico anti-HIV studies†

A series of Imidazo[1,2-a]pyridine-Schiff base derivatives were synthesized and characterized using 1H NMR, 13C NMR, Mass Spectrometry and FTIR techniques, and the structure of 4a was further confirmed through single-crystal X-ray diffraction analysis. Density Functional Theory (DFT) has been used to investigate the structural and electronic properties. The synthesized compounds were evaluated in vitro for their antiviral activity against human immunodeficiency virus type-1 (HIV-1) and human immunodeficiency virus type-2 (HIV-2) in MT-4 cells. Compound 4a displayed EC50 values of 82,02 and 47,72 μg ml−1 against HIV-1 and HIV-2, respectively. Molecular docking studies were conducted to gain insights into the interaction mechanism of the synthesized compounds with HIV-1 reverse transcriptase. ADME analysis suggested acceptable pharmacokinetic profiles, though solubility remains a limitation for these compounds, highlighting the need for further structural modifications to enhance bioavailability and therapeutic potential.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
RSC Advances
RSC Advances chemical sciences-
CiteScore
7.50
自引率
2.60%
发文量
3116
审稿时长
1.6 months
期刊介绍: An international, peer-reviewed journal covering all of the chemical sciences, including multidisciplinary and emerging areas. RSC Advances is a gold open access journal allowing researchers free access to research articles, and offering an affordable open access publishing option for authors around the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信